Know Cancer

or
forgot password
  • cancer clinical trials in mentor, OH

  • Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Endometrial Cancer
    Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer
    Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
    Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
    Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Head and Neck Cancer
    Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Hereditary Breast/Ovarian Cancer (brca1, brca2), Osteoporosis, Ovarian Cancer
    ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Cervical Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
    Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Prostate Cancer
    VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Recurrent Endometrial Carcinoma
    Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Endometrial Cancer
    Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Gestational Trophoblastic Tumor
    Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
    AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Lung Cancer
    Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Cognitive/Functional Effects, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Changes
    Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Breast Cancer
    OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
    Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Brain and Central Nervous System Tumors
    Collecting Tumor Samples From Patients With Gynecological Tumors
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Cancer
    Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Prostate Cancer, Sexual Dysfunction
    Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Prostate Cancer
    Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Stage IV Prostate Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
    Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
    Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Psychosocial Effects of Cancer and Its Treatment
    Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma
    Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Recurrent Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Leiomyosarcoma
    AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
    Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Lung Cancer
    Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Cognitive/Functional Effects, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Ovarian Mucinous Cystadenocarcinoma, Ovarian Mucinous Cystadenoma With Proliferating Activity, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Epithelial Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Epithelial Cancer, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Epithelial Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer
    EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma
    Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma
    Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Breast Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
    Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
    Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Stage IB Esophageal Cancer, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer
    Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
    Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
    Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Head and Neck Cancer, Precancerous Condition
    Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Prostate Cancer
    Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
    Lake/University Ireland Cancer Center
    Mentor, Ohio 44060
    Anxiety Disorder, Fallopian Tube Cancer, Fatigue, Nausea and Vomiting, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
    Great Lakes Gastroenterology

    Trial Locations
    Great Lakes Gastroenterology
    The Endoscopy Center of Lake County
    Crohn's Disease
    Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
    Great Lakes Gastroenterology

    Trial Locations
    Great Lakes Gastroenterology
    The Endoscopy Center of Lake County
    Crohn's Disease
    Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Lake University Ireland Cancer Center
    Mentor, Ohio 44060
    BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer